Teva Pharmaceuticals is the leading generic drug company in the United States. Teva now represents 21% of US generic prescriptions, with 1 of every 6 US prescriptions being filled with a Teva product. Teva introduced 18 generic products in 2010, and had 188 ANDAs pending FDA approval as of June 20, 2011. The company markets the broadest product line in the country, with nearly 400 generic products in over 1200 dosage strengths and packaging sizes, covering all major therapeutic categories.
The Global Leader
Teva’s parent company, Teva Pharmaceutical Industries Limited, is the leading generic drug company in the world in terms of both total and new prescriptions. The company’s global presence covers North America, Europe, Latin America, Asia, and Israel, with approximately 60% of its sales generated in North America. Teva now has approximately 40,000 employees, including nearly 6000 within the United States, and annual net sales that totaled $16.1 billion in 2010. Teva operates in approximately 60 countries, including 40 finished dosage pharmaceutical manufacturing sites, 28 pharmaceutical R&D centers, and 21 active pharmaceutical ingredient (API) manufacturing sites around the world, with all pharmaceutical production facilities maintaining a uniform quality standard.
Diversified and Vertically Integrated
In addition to its leadership in the generics market, Teva has a significant and growing branded pharmaceutical portfolio, including COPAXONE® for multiple sclerosis, AZILECT® for Parkinson’s disease, ProAir® for respiratory disorders, and a sizable women’s health portfolio. The company’s wellestablished and balanced portfolio is supported by a vertically integrated API business. This vertical integration ensures that as Teva continues to grow, the company can maintain its high standard of quality and efficiency and its longstanding commitment to customer satisfaction.
Innovation for Long-Term Growth
Teva has identified biopharmaceuticals—in particular, biosimilars—as an important long-term growth opportunity, and has established a dedicated research, development, and manufacturing capability. The company’s joint venture with Switzerland-based Lonza Group Ltd provides access to the expertise and infrastructure of the world’s largest producer of biological API. Teva’s biopharmaceutical R&D facilities specialize in different technologies, including the proprietary albumin fusion technology, which can be used to create longacting biological products.
Leading the Way to Affordable Health Care
Teva’s vision is to make quality health care accessible. The company’s Government Affairs team occupies an office on Capitol Hill and works on behalf of American consumers to advance both innovation and patient access to needed therapies. Teva also recently launched the smart-health.com Web site, where consumers can learn about generic pharmaceuticals and why they are an important element of high-quality, affordable health care. Teva is the leading provider of affordable generic medicines. Its robust pipeline of future products is a source of continuing value to American consumers. PT
For more information, visit www.tevausa.com.
Donepezil Hydrochloride Tablets, AB rated to Aricept®. Available in 5- and 10-mg strengths.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs